Abstract
Natural products from plants are an excellent source of Human pancreatic α-amylase (HPA) inhibitors which have therapeutic application as oral agents to control blood glucose levels. The mechanism of action by Bisdemethoxycurcumin (BDMC) has been reported, isolated from Curcuma longa rhizomes, which inactivates HPA, a target for type-2 diabetes. This study validates its mode of action and its target which has to date remained largely unknown. The cytotoxicity and bioactivity of crude extract and BDMC on the pancreatic acinar AR42J secretory model cell line were evaluated with LD50 value of 16.25 μg ml-1 and 63.53 μM, and secretory α-amylase inhibition of 41% and 30%, respectively. BDMC uncompetitively inhibits HPA (Ki' of 10.1μM) and a binding affinity (Ka) of 8.5 x 104 M-1 with the involvement of surface exposed aromatic residues. The thermodynamic parameters suggest that binding is both enthalpically and entropically driven with ΔGº of - 28.13 kJ mol-1. Computational ligand docking showed that inactivation depends on hydrogen bonding and π-π interactions. Thus, BDMC, a natural product could be lowering post-prandial glycemia via a novel mode of binding and inactivation of HPA and may proved to be a good drug candidate to reduce/control post-prandial hyperglycemia.
Keywords: Human pancreatic α-amylase, bisdemethoxycurcumin, ligand binding, AR42J cell line, docking
The Natural Products Journal
Title:Deciphering the Inactivation of Human Pancreatic α-Amylase, an Antidiabetic Target, by Bisdemethoxycurcumin, a Small Molecule Inhibitor, Isolated from Curcuma longa
Volume: 3 Issue: 1
Author(s): Sudha Ponnusamy, Smita Zinjarde, Shobha Bhargava, Urmila Kulkarni-Kale, Sangeeta Sawant and Ameeta Ravikumar
Affiliation:
Keywords: Human pancreatic α-amylase, bisdemethoxycurcumin, ligand binding, AR42J cell line, docking
Abstract: Natural products from plants are an excellent source of Human pancreatic α-amylase (HPA) inhibitors which have therapeutic application as oral agents to control blood glucose levels. The mechanism of action by Bisdemethoxycurcumin (BDMC) has been reported, isolated from Curcuma longa rhizomes, which inactivates HPA, a target for type-2 diabetes. This study validates its mode of action and its target which has to date remained largely unknown. The cytotoxicity and bioactivity of crude extract and BDMC on the pancreatic acinar AR42J secretory model cell line were evaluated with LD50 value of 16.25 μg ml-1 and 63.53 μM, and secretory α-amylase inhibition of 41% and 30%, respectively. BDMC uncompetitively inhibits HPA (Ki' of 10.1μM) and a binding affinity (Ka) of 8.5 x 104 M-1 with the involvement of surface exposed aromatic residues. The thermodynamic parameters suggest that binding is both enthalpically and entropically driven with ΔGº of - 28.13 kJ mol-1. Computational ligand docking showed that inactivation depends on hydrogen bonding and π-π interactions. Thus, BDMC, a natural product could be lowering post-prandial glycemia via a novel mode of binding and inactivation of HPA and may proved to be a good drug candidate to reduce/control post-prandial hyperglycemia.
Export Options
About this article
Cite this article as:
Ponnusamy Sudha, Zinjarde Smita, Bhargava Shobha, Kulkarni-Kale Urmila, Sawant Sangeeta and Ravikumar Ameeta, Deciphering the Inactivation of Human Pancreatic α-Amylase, an Antidiabetic Target, by Bisdemethoxycurcumin, a Small Molecule Inhibitor, Isolated from Curcuma longa, The Natural Products Journal 2013; 3 (1) . https://dx.doi.org/10.2174/2210315511303010005
DOI https://dx.doi.org/10.2174/2210315511303010005 |
Print ISSN 2210-3155 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-3163 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Strategies Targeting Soluble β-Amyloid Oligomers and their Application to Early Diagnosis of Alzheimer’s Disease
Current Alzheimer Research Comparison Between Computed Tomography Angiography and Digital Subtraction Angiography in Critical Lower Limb Ischemia
Current Medical Imaging Contemporary Overview on Clinical Trials and Future Prospects of Hepato-protective Herbal Medicines
Reviews on Recent Clinical Trials Stroke Risk Stratification Schemes in Atrial Fibrillation in the Era of Non- Vitamin K Anticoagulants: Misleading and Obsolete, At Least for the “Low-Risk” Patients?
Current Drug Targets Subject Index To Volume 6
Central Nervous System Agents in Medicinal Chemistry Inflammatory Bowel Disease in Migrant Populations: Should we Look Even Further Back?
Current Drug Targets Protocatechuic Acid and Human Disease Prevention: Biological Activities and Molecular Mechanisms
Current Medicinal Chemistry The Prevalence of Frailty in Patients Admitted to Hospital with Vertebral Fragility Fractures
Current Rheumatology Reviews MicroRNA-mediated MMP Regulation: Current Diagnostic and Therapeutic Strategies for Metabolic Syndrome
Current Gene Therapy Prophylaxis of Venous Thromboembolism in Major Orthopedic Surgery: A Practical Approach
Cardiovascular & Hematological Agents in Medicinal Chemistry GABAergic Pharmacotherapy in the Treatment of Motor Disorders of the Central Nervous System
Current Pharmaceutical Design Autoimmune Channelopathies of the Nervous System
Current Neuropharmacology Recent Medicinal Chemistry Approach for the Development of Dipeptidyl Peptidase IV Inhibitors
Current Medicinal Chemistry Glucocorticoids in Pregnancy
Current Pharmaceutical Biotechnology Non Invasive Indexes for the Assessment of Patients with Non-alcoholic Fatty Liver Disease
Current Pharmaceutical Design The Nutrigenetics and Pharmacogenetics of Vitamin D Pathways
Current Pharmacogenomics and Personalized Medicine LncRNA PVT1 as a Novel Biomarker for Diabetes-related Complications
Current Medicinal Chemistry Leptin and the Ob-Receptor as Anti-Obesity Target: Recent In Silico Advances in the Comprehension of the Protein-Protein Interaction and Rational Drug Design of Anti- Obesity Lead Compounds
Current Pharmaceutical Design Pharmacogenetic Variation and Metformin Response
Current Drug Metabolism Review of Recent Clinical Developments and Patents for the Treatment of Autoimmune and Inflammatory Diseases by Mesenchymal Stromal Cells
Recent Patents on Regenerative Medicine